Hoth Therapeutics, Inc.

Analysis for Ticker: HOTH

Hoth Therapeutics Inc develops treatments for conditions like cancer toxicities, Alzheimer disease, and obesity, but it functions as a mechanism to transform public investment into executive compensation. By 01/2026, the company had accumulated a deficit of 72,9$ million without ever generating revenue from a single product sale. This is a business where the math of survival is a terminal spiral. Imagine a company that pays its leaders millions of dollars to manage science experiments that never make money. To pay these leaders, the company prints new shares of stock, which acts like adding more water to a soup until the flavor disappears for everyone who already owns a bowl.